文献速递消化道肿瘤放疗姑息放疗与转移瘤放疗物理与技术

新辅助再程放化疗联合手术与术中电子线放疗治疗局部复发直肠癌

Neoadjuvant chemo-reirradiation followed by resection and intraoperative electron beam radiotherapy: outcomes of multimodality treatment for locally recurrent rectal cancer.
PubMed 文献 · Radiat Oncol · 2025-12-23

本回顾性研究纳入2021年9月至2024年12月接受再程放化疗后手术联合术中电子线放疗(IOERT)的40例局部复发直肠癌(LRRC)患者,中位累积肿瘤剂量113 Gy(α/β=10 Gy)。未观察到4级或5级毒性,急性3级毒性见于14/37(38%)患者,晚期3级毒性见于13/30(43%);中位随访21个月后,2年总生存(OS)率为75.7%,局部再复发无生存(LRFS)率为37.2%。结论认为该多模式方案在此前已放疗的高危人群中毒性可接受且肿瘤学结局良好。

要点

  • 再程放化疗联合手术与IOERT未出现4级或5级毒性。
  • 急性3级毒性38%,晚期3级毒性43%,以勃起功能障碍和肾脏疾病为主。
  • 2年OS率75.7%,2年LRFS率37.2%。

核心结论

  • 在此前已放疗的局部复发直肠癌患者中,再程放化疗联合广泛手术与IOERT显示出可接受的治疗相关毒性和良好的肿瘤学结局。

研究设计与样本

  • 回顾性研究,纳入2021年9月至2024年12月接受再程放化疗及手术联合IOERT的40例局部复发直肠癌患者,中位累积肿瘤剂量113 Gy(α/β=10 Gy)。

主要发现

  • 未观察到4级或5级毒性。
  • 急性累积治疗相关3级毒性发生于14/37(38%)患者,主要为勃起功能障碍(5/37,14%)、脓肿形成(4/37,11%)或周围神经病变(2/37,5%)。
  • 晚期3级毒性发生于13/30(43%)患者,主要包括勃起功能障碍(5/30,17%)、肾脏疾病(5/30,17%)或周围神经病变(2/30,7%)。
  • 术后中位随访21个月(IQR 12-32),2年总生存率为75.7%,2年局部再复发无生存率为37.2%。

关键数值与推荐

  • 毒性按CTCAE记录于前瞻性维护的数据库。
  • 中位累积肿瘤剂量113 Gy(α/β=10 Gy)。
  • 急性3级毒性14/37(38%),晚期3级毒性13/30(43%)。
  • 2年OS率75.7%,2年LRFS率37.2%。

临床怎么用

  • 对于此前已放疗的局部复发直肠癌患者,可考虑再程放化疗联合手术与IOERT的多模式治疗,但需关注累积毒性。

局限性

  • 回顾性研究设计。
  • 样本量较小(40例)。
  • 随访时间较短(中位21个月)。
  • 需要更长期随访以识别与治疗相关毒性相关的风险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemo-reirradiation has emerged as a feasible neoadjuvant therapy to improve resectability in locally recurrent rectal cancer (LRRC). However, its combination with surgery and intraoperative electron radiotherapy (IOERT) raises concerns regarding cumulative toxicity. This retrospective study aimed to evaluate acute and late toxicity profiles, local control and survival outcomes, following this multimodal approach in our institution. METHODS: LRRC patients who underwent chemo-reirradiation and surgery with IOERT (median cumulative tumour dose of 113 Gy, α/β = 10 Gy) between September 2021 to December 2024 were retrospectively analysed. Acute and late treatment-related toxicities (CTCAE) were recorded in a prospectively maintained database. Secondary outcomes were overall survival (OS) and local re-recurrence-free survival (LRFS). RESULTS: Among 40 patients, no grade 4 or 5 toxicities were observed. Acute cumulative treatment-related grade 3 toxicities occurred in 14/37 (38%) patients, predominantly consisting of erectile dysfunction (5/37, 14%), abscess formation (4/37, 11%) or peripheral neuropathy (2/37, 5%). Late grade 3 toxicities occurred in 13/30 (43%) patients, comprising mainly of erectile dysfunction (5/30, 17%), renal disorders (5/30, 17%) or peripheral neuropathy (2/30, 7%). After a median follow-up period of 21 months (IQR 12-32) after surgery, 2-year overall survival (OS) and local re-recurrence-free survival (LRFS) were 75.7% and 37.2%, respectively. CONCLUSION: In previously irradiated LRRC patients, a multimodality approach combining chemo-reirradiation and extensive surgery with IOERT demonstrated acceptable treatment-related toxicities and favourable oncological outcomes for this high-risk population. Further research with longer follow-up is warranted to identify risk factors associated with treatment-related toxicity.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Vande Kerckhove FEC, Piqeur F, Banken E, et al. Neoadjuvant chemo-reirradiation followed by resection and intraoperative electron beam radiotherapy: outcomes of multimodality treatment for locally recurrent rectal cancer. Radiat Oncol. 2025. PMID: 41437065. doi:10.1186/s13014-025-02782-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。